ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Sold by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D lowered its stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 10.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 101,753 shares of the biotechnology company’s stock after selling 11,854 shares during the period. State of New Jersey Common Pension Fund D’s holdings in ADMA Biologics were worth $1,745,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in ADMA. Nkcfo LLC acquired a new position in ADMA Biologics during the fourth quarter worth $325,000. Rhumbline Advisers lifted its stake in ADMA Biologics by 1.0% during the 4th quarter. Rhumbline Advisers now owns 621,079 shares of the biotechnology company’s stock worth $10,651,000 after acquiring an additional 5,881 shares in the last quarter. New York State Teachers Retirement System grew its position in ADMA Biologics by 24.1% in the 4th quarter. New York State Teachers Retirement System now owns 113,090 shares of the biotechnology company’s stock valued at $1,939,000 after acquiring an additional 21,976 shares in the last quarter. Van ECK Associates Corp purchased a new stake in ADMA Biologics during the fourth quarter worth about $3,424,000. Finally, Allspring Global Investments Holdings LLC lifted its position in shares of ADMA Biologics by 1,144.4% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company’s stock worth $51,016,000 after purchasing an additional 2,613,482 shares in the last quarter. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

ADMA Biologics Price Performance

NASDAQ:ADMA opened at $15.44 on Wednesday. The firm has a market cap of $3.65 billion, a price-to-earnings ratio of 55.14 and a beta of 0.75. ADMA Biologics, Inc. has a 12-month low of $5.08 and a 12-month high of $23.64. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The company’s 50-day moving average is $16.90 and its two-hundred day moving average is $18.02.

Analysts Set New Price Targets

A number of research analysts recently issued reports on ADMA shares. HC Wainwright lifted their target price on ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a report on Friday, November 8th. Raymond James boosted their price objective on ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research report on Friday, November 8th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.